RocRock Biotechnology

Based in Suzhou, China, and founded in 2021, Rock Roc Biotechnology Co. , Ltd, RocRock Bio operates as a provider of engineered macrophage technology, focusing on the development and clinical application of macrophage drugs for the treatment of solid tumors. The branches have been set up in Shenzhen and Berlin. The founder, Dr.

Xiushan Yin, is a senior researcher at Karolinska Medical School. Its core team members were from scientific research institutions such as the European Molecular Biology Laboratory and the German National Center for Molecular Medicine. The company has completed the declaration and approval of nearly 40 patents and established partnerships with SYPM, and Peking Union Medical College Hospital. In March 2025, the company closed a pre-series A+ funding from an individual investor.

In November 2025, RocRock Biotechnology raised CNY 50 million in series A funding. RocRock Bio's core platforms include the "24H-CAR" technology platform for chimeric antigen receptor macrophage (CAR-M) preparation, the "ADM-CAR" enhanced synthesis platform based on iterative screening of macrophage activation structural domains, the "Del-M" macromolecule delivery platform using macrophages as carriers, and the "M-DB" subtype database and target database platform. The platforms and drugs can be used to treat breast cancer, lung cancer, liver cancer, and other rare diseases. The company generates revenue by developing drugs targeting solid tumor cells.

The company will use the latest funding to further advance its globally leading macrophage drug research and development and clinical translation.